highperformr logo

BlackThorn Therapeutics's Overview

Total employees65
HeadquartersSouth San Francisco
Founded2015

BlackThorn Therapeutics was a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for neurobehavioral disorders. Their approach leveraged proprietary data, computational psychiatry, and brain imaging to identify and validate novel drug targets. BlackThorn aimed to create precision medicines for conditions like depression, anxiety, and other central nervous system disorders. In October 2020, BlackThorn Therapeutics was acquired by Neumora Therapeutics, a company launched with a similar mission to advance precision medicines for brain diseases. BlackThorn's assets and expertise were integrated into Neumora's platform.

Where is BlackThorn Therapeutics's Headquarters?

HQ Function

The headquarters served as the central hub for research and development, clinical operations, corporate strategy, and administrative functions, driving the company's efforts in discovering and developing treatments for neurobehavioral disorders.

Notable Features:

As a biotech company in a prominent innovation district, the facility likely featured advanced laboratory spaces for neuroscience research, drug discovery, and biomarker development, alongside modern office environments designed for collaboration.

Work Culture:

The work culture at BlackThorn Therapeutics likely emphasized scientific rigor, innovation, collaboration between multidisciplinary teams (neuroscience, data science, clinical development), and a strong patient-centric focus, driven by the urgency to address unmet needs in mental health.

HQ Significance:

Its location in South San Francisco provided BlackThorn with access to a rich ecosystem of talent, research institutions, potential partners, and investors, crucial for a company in the competitive biopharmaceutical landscape.

Values Reflected in HQ: The headquarters would have reflected BlackThorn's commitment to scientific excellence, data-driven approaches, and the pursuit of innovative solutions for complex brain disorders.

Location:

As a clinical-stage biopharmaceutical company, BlackThorn Therapeutics' global presence was primarily related to its clinical trial activities. While its physical operations were centralized in South San Francisco, its research and development programs, particularly clinical trials for its drug candidates, may have involved collaborations with investigators and sites in multiple countries to ensure diverse patient populations and robust data collection.

Street Address:

400 Oyster Point Blvd, Suite 222

City:

South San Francisco

State/Province:

CA

Country:

USA

BlackThorn Therapeutics's Global Presence

Buying Intent Signals for BlackThorn Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of BlackThorn Therapeutics

As of April 2025, BlackThorn Therapeutics' leadership includes:

Bill Martin, Ph.D. - President and Chief Executive Officer
Scott Forrest, M.B.A. - Chief Financial Officer
Jane Tuvell, M.B.A. - Chief Business Officer
Anil K. Reddy, M.D. - Senior Vice President, Translational & Experimental Medicine
Frank S. Menniti, Ph.D. - Chief Scientific Officer

Investors of BlackThorn Therapeutics

BlackThorn Therapeutics has been backed by several prominent investors over the years, including:

ARCH Venture Partners
GV (formerly Google Ventures)
Biomatics Capital
Altitude Life Science Ventures
Polaris Partners
Alexandria Venture Investments
Mercury Fund
Johnson & Johnson Innovation – JJDC, Inc.

Executive New Hires/Exits in the Last 12 Months

Hire0
Exits0

BlackThorn Therapeutics was acquired by Neumora Therapeutics in October 2020. Therefore, there have been no executive hires or exits for BlackThorn Therapeutics as an independent entity in the last 12 months. All significant leadership changes occurred around the time of the acquisition.

Technology (Tech Stack) used by BlackThorn Therapeutics

Discover the tools BlackThorn Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

BlackThorn Therapeutics Email Formats and Examples

Historically, BlackThorn Therapeutics likely used common corporate email formats based on its domain blackthornrx.com. As the company was acquired and the domain is no longer active for email, these formats are purely historical.

[first_initial][last]@blackthornrx.com

Format

jdoe@blackthornrx.com

Example

0%

Success rate

News and media

Neumora TherapeuticsOctober 13, 2020

Neumora Therapeutics Launches with $500 Million Financing and Acquisition of BlackThorn Therapeutics to Pioneer a New Era of Precision Medicines for Brain Diseases

Neumora Therapeutics announced its launch with a $400 million Series A financing and an additional $100 million in potential pharma R&D collaborations. Concurrently, Neumora acquired BlackThorn Therapeutics, integrating its pipeline, technology, and team to advance precision medicines for brain diseases....more

PR NewswireJanuary 7, 2020

BlackThorn Therapeutics Announces Positive Topline Results from Phase 2 Study of BTRX-324 (formerly BCI-540) in Major Depressive Disorder

BlackThorn Therapeutics reported positive topline results from its Phase 2 TACHYON study of BTRX-324, a kappa opioid receptor antagonist, in patients with major depressive disorder. The study met its primary endpoint, showing a statistically significant reduction in depressive symptoms....more

PR NewswireJuly 17, 2018

BlackThorn Therapeutics Announces $60 Million Series B Financing to Advance Pipeline of Targeted Treatments for Neurobehavioral Disorders

BlackThorn Therapeutics secured $60 million in a Series B financing round. The funding was intended to advance its pipeline of novel, targeted therapeutics for neurobehavioral disorders, including its lead clinical candidate for major depressive disorder and its preclinical programs....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including BlackThorn Therapeutics, are just a search away.